IceCure Medical Ltd (ICCM)
NASDAQ: ICCM · Real-Time Price · USD
3.080
0.00 (0.00%)
At close: Aug 7, 2026, 4:00 PM EDT
3.120
+0.040 (1.30%)
After-hours: Aug 7, 2026, 7:50 PM EDT
IceCure Medical Revenue
IceCure Medical had revenue of $911.00K in the quarter ending March 31, 2026, with 25.66% growth. This brings the company's revenue in the last twelve months to $3.57M, up 8.92% year-over-year. In the year 2025, IceCure Medical had annual revenue of $3.38M with 2.67% growth.
Revenue (ttm)
$3.57M
Revenue Growth
+8.92%
P/S Ratio
2.96
Revenue / Employee
$51,667
Employees
69
Market Cap
10.55M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.38M | 88.00K | 2.67% |
| Dec 31, 2024 | 3.29M | 62.00K | 1.92% |
| Dec 31, 2023 | 3.23M | 144.00K | 4.67% |
| Dec 31, 2022 | 3.09M | -1.05M | -25.45% |
| Dec 31, 2021 | 4.14M | 270.00K | 6.98% |
| Dec 31, 2020 | 3.87M | 2.24M | 137.74% |
| Dec 31, 2019 | 1.63M | 546.77K | 50.62% |
| Dec 31, 2018 | 1.08M | 389.12K | 56.30% |
| Dec 31, 2017 | 691.11K | 65.85K | 10.53% |
| Dec 31, 2016 | 625.25K | -139.86K | -18.28% |
| Dec 31, 2015 | 765.11K | -302.14K | -28.31% |
| Dec 31, 2014 | 1.07M | 711.63K | 200.11% |
| Dec 31, 2013 | 355.62K | 60.86K | 20.65% |
| Dec 31, 2012 | 294.76K | 189.18K | 179.17% |
| Dec 31, 2011 | 105.58K | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
| Dec 31, 2007 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| IRIDEX | 52.58M |
| Trinity Biotech | 43.79M |
| NeuroOne Medical Technologies | 12.72M |
| Picard Medical | 5.47M |
| Sintx Technologies | 1.03M |
| Co-Diagnostics | 718.17K |
| Nexalin Technology | 275.58K |
| Adagio Medical Holdings | 137.00K |
ICCM News
- 3 days ago - IceCure Medical Adds Adventist Health as U.S. Clinical Site for its Post-Marketing "ChoICE" Study for Low-Risk Breast Cancer Cryoablation Treatment - PRNewsWire
- 4 days ago - IceCure Medical to Report First Half 2026 Financial and Operating Results on August 12, 2026 - PRNewsWire
- 11 days ago - IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance of ProSense® - PRNewsWire
- 13 days ago - IceCure Medical Kicks Off its Post-Marketing "ChoICE" Study for the Low-Risk Breast Cancer Treatment at First U.S Clinical Site - PRNewsWire
- 26 days ago - IceCure Medical expands U.S. commercial team for ProSense cryoablation - TheFly
- 26 days ago - IceCure Expands U.S. Commercial Team to Meet Surging Demand for ProSense® Cryoablation - PRNewsWire
- 26 days ago - IceCure Medical Slides: Investor presentation - Filings
- 4 weeks ago - IceCure Medical highlights expanding commercial adoption of ProSense - TheFly